Glenmark and Forest Labs settle Savella litigation

India-based life sciences company Glenmark Pharmaceuticals has confirmed that it has ended its patent dispute with Forest Laboratories.

The dispute was provoked by Glenmark’s Abbreviated New Drug Application to market a generic version of the Savella (milnacipran) drug.

Savella, produced by Forest Laboratories, is a drug used to manage fibromyalgia, widespread pain, within the human body.

Forest Laboratories sued Glenmark in February 2014 at the US District Court for the District of Delaware, alleging the infringement of three of its patents.

But under the terms of the agreement, announced today, December 21, Glenmark has the right to market the Savella drug or an authorised generic version.

Further details of the agreement were not disclosed.

According to IMS Health, between October 2014 and 2015 Savella generated $134.7 million in sales.